Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis

NCT04535349 | Recruiting

• 1 other identifier: 19-226
• Study Type: interventional
• Target: 35
• Locations: 1 country
• Sites: 2

Brief Summary

Introduction: Transthyretin cardiac amyloidosis (ATTR) is an important cause of heart failure. Cardiac planar radionuclide imaging using 99mTc-labeled bone seeking radiopharmaceuticals is used as a noninvasive diagnostic criterion in patients without detectable monoclonal protein. The visual assessment remains the main noninvasive criterion for the diagnosis. Medical therapy using tafamidis meglumine that binds to transthyretin and prevents amyloidogenesis, recently demonstrated a reduction in all-cause mortality and cardiovascular-related hospitalizations. As a consequence, there is a need for quantitative approaches that would be useful for diagnosis and prognosis assessment but also for the evaluation of patient therapeutic response. Materials and methods: The investigators aim to include 35 patients with a suspected diagnosis of cardiac ATTR amyloidosis in whom a cardiac planar radionuclide imaging using 99mTc-labeled bone seeking radiopharmaceuticals is planned as part of routine noninvasive diagnosis work-up. Using a test-retest approach, the aim is to compare a quantitative method vs. conventional semi-quantitative approaches for the assessment of cardiac uptake of bone radiopharmaceuticals using new 3D CZT-based SPECT-CT cameras in patients with suspected cardiac ATTR amyloidosis. The investigators estimated that 20 patients will have a diagnosis of cardiac ATTR amyloidosis. In the latter patients, the aim is to evaluate the impact of 6-month therapy using tafamidis on quantitative and semi-quantitative assessment of cardiac uptake of bone radiopharmaceuticals Perspectives: This new non invasive imaging techniques for the quantitative assessment of the amyloid burden in patients with cardiac ATTR amyloidosis may help identify the responders and the patients who should benefit from dose intensification.

Conditions

Amyloidosis Transthyretin

Outcome Measures

Primary Outcomes (3)

• Test-retest reproducibility

  Test-retest repeatability will be assessed by comparing the results from two successive 3D CZT imaging examinations performed in two distinct baseline imaging sessions. Repeatability will be evaluated by the mean absolute difference and the coefficient of variation (COV) (mean relative difference) between the results of the assessment of the 3D-myocardial uptake of bone tracers in the two examinations. A measurement will be considered reproducible when COV will be below 20%. Furthermore, the repeatability will also be assessed using the interclass correlation coefficient (ICC) and its 95% confidence interval (95%CI) under an ANOVA random effect model, and Bland Altman plots.

  10 days

• Correlations between the quantitative assessment of the myocardial uptake of bone tracers and semi-quantitative approaches

  Correlations between the quantitative assessment of the myocardial uptake (COV) of bone tracers and semi-quantitative approaches will be performed by using linear regression analysis performed by the least squares method and Pearson's correlation coefficient r and Bland Altman plots.

  10 days

• Comparison between the quantitative assessment of the myocardial uptake of bone tracers (COV) between baseline and follow-up imaging of each patient, 6 months after the beginning of the treatment by tafamidis

  The investigators will compare baseline and follow-up imaging of each patient, 6 months after the beginning of the treatment by tafamidis using paired comparison for quantitative data and concordance tests (Kappa test) for semi-quantitative data.

  6 months

Study Arms (3)

No cardiac ATTR amyloidosis

OTHER

Cardiac echocardiography at baseline and whole-body \& CZT bone tracer imaging (SPECT). day 3 - day 10 : second whole-body \& CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging Perugini 0 : no cardiac TTR amyloidosis No further follow-up.

Diagnostic Test: Whole-body & CZT bone tracer imaging (SPECT)

Cardiac ATTR amyloidosis, no treatment with tafamidis planned

OTHER

Cardiac echocardiography at baseline and whole-body \& CZT bone tracer imaging (SPECT). day 3 - day 10 : second whole-body \& CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis but no treament with tafamidis planned. Cardiac echocardiography at 3 months and whole-body \& CZT bone tracer SPECT and cardiac echocardiography at 6 months

Diagnostic Test: Whole-body & CZT bone tracer imaging (SPECT)

Cardiac ATTR amyloidosis, treatment with tafamidis planned

OTHER

Cardiac echocardiography at baseline and whole-body \& CZT bone tracer imaging (SPECT). day 3 - day 10 : second whole-body \& CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis. Start of the treament with tafamidis. Cardiac echocardiography at 3 months and whole-body \& CZT bone tracer SPECT and cardiac echocardiography at 6 months

Diagnostic Test: Whole-body & CZT bone tracer imaging (SPECT)

Interventions

Whole-body & CZT bone tracer imaging (SPECT) DIAGNOSTIC_TEST

Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras

Cardiac ATTR amyloidosis, no treatment with tafamidis planned; Cardiac ATTR amyloidosis, treatment with tafamidis planned; No cardiac ATTR amyloidosis

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Medical history of Heart Failure (HF) with at least 1 prior hospitalization for HF or clinical evidence of HF (without hospitalization) manifested by signs or symptoms of volume overload or elevated intracardiac pressures that required/requires treatment with a diuretic for improvement, and an increase of BNP \>200 pg/mL and/or NT-proBNP \>500 pg/mL
• Suspected cardiac ATTR amyloidosis
• Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness \> 12 mm
• Patient signed consent
• Contraception method

You may not qualify if:

• New York Heart Association (NYHA) functional class IV despite diuretic treatment
• Life expectancy \<6 month due to the severity of cardiac amyloidosis and/or comorbidities
• Aortic valve surgical or percutaneous replacement within 30 days or planned within months
• Presence of primary (light chain) amyloidosis
• Contraindication to tafamidis
• Pregnancy and breast feeding ; pregnancy test in women of reproductive age irrespective of contraception method)
• Adults with protective measures

Sponsors & Collaborators

• University Hospital, Caen: lead
• Pfizer: collaborator

Study Sites (2)

CHU de Caen

Caen, 14000, France

RECRUITING

Clinique du Bois

Lille, 59000, France

RECRUITING

Related Publications (1)

• Legallois D, Turcan L, Agostini D, Manrique A. Test-retest reproducibility of myocardial 99mTc-HMDP uptake quantification by SPECT-CT in suspected transthyretin cardiac amyloidosis. J Nucl Cardiol. 2025 Sep;51:102273. doi: 10.1016/j.nuclcard.2025.102273. Epub 2025 Jun 13.

  PMID: 40518108 DERIVED

MeSH Terms

Conditions

Amyloid Neuropathies, Familial

Interventions

Tomography, Emission-Computed, Single-Photon

Condition Hierarchy (Ancestors)

Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Nervous System Diseases; Amyloid Neuropathies; Peripheral Nervous System Diseases; Neuromuscular Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Amyloidosis, Familial; Metabolism, Inborn Errors; Metabolic Diseases; Nutritional and Metabolic Diseases; Amyloidosis; Proteostasis Deficiencies

Intervention Hierarchy (Ancestors)

Tomography, Emission-Computed; Image Interpretation, Computer-Assisted; Diagnostic Imaging; Diagnostic Techniques and Procedures; Diagnosis; Image Enhancement; Photography; Radionuclide Imaging; Tomography; Diagnostic Techniques, Radioisotope

Central Study Contacts

Damien Legallois, MD

CONTACT

33230165709; damien.legallois@unicaen.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 17, 2020
• First Posted: September 1, 2020
• Study Start: October 8, 2020
• Primary Completion: June 15, 2025
• Study Completion: June 15, 2025
• Last Updated: January 31, 2025

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

FR (2)